Anemia in Chronic Kidney Disease
New Avenues to Improve Patient Outcomes
Clinical Management Guidelines
Drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease.
US Food and Drug Administration. Updated August 4, 2017. Accessed November 3, 2022.
Patient Resources
Informational resources for patients who have anemia and chronic kidney disease.
Anemia in chronic kidney disease.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Suggested Readings
Overview, Epidemiology, Pathophysiology
The influence of inflammation on anemia in CKD patients.
Gluba-Brzόzka A, et al. Int J Mol Sci. 2020;21(3):725.
Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States.
St. Peter WL, et al. BMC Nephrol. 2018;19(1):67.
Vadadustat in patients with anemia and non-dialysis-dependent CKD.
Chertow GM, et al. N Engl J Med. 2021;384(17):1589-1600.
Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study.
Fishbane S, et al. J Am Soc Nephrol. 2022;33(4):850-866.
HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.
Haase VH. Hemodial Int. 2017;21(suppl 1):S110-S124.
A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps.
Lopes MB, et al. Sci Rep. 2021;11(1):1784.
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA, et al; for the TREAT Investigators. N Engl J Med. 2009;361(21):2019-2032.
Daprodustat for the treatment of anemia in patients not undergoing dialysis.
Singh AK, et al. N Engl J Med. 2021;385(25):2313-2324.
Singh AK, et al. JAMA Intern Med. 2022;182(6):592-602.
Anemia in Chronic Kidney Disease: New Avenues to Improve Patient Outcomes
Anemia in Chronic Kidney Disease: New Avenues to Improve Patient Outcomes
Relevant Resources
Mechanism-Based Strategies to Achieve Patient-Centered Care
Improved Diagnostic and Management Strategies
Patient-Centered Management of Hyperglycemia in Primary Care
Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens
Translating Research Into Practice
Translating Reseach Into Practice
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Discussions and Debates Around GLP-1 Receptor Agonists
Evolving Roles of GLP-1 Receptor Agonists
Individualizing Evidence-Based Care
Evolving Strategies for Diagnosis and Long-Term Management
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Best Practices in Diagnosis and Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
New Strategies for Insulin Replacement Therapy
Consensus and Controversies Around Intensifying Noninsulin Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Evolving Roles of GLP-1 Receptor Agonists
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Looking Beyond Hemoglobin A1c
Debates & Discussions on the Evolving Role of JAK Inhibitors
What You Need to Know
Mechanistic Insights and Evolving Treatment Options
The Evolving Role of JAK Inhibitors
Implications for PCSK9 Inhibitors in Clinical Practice
Unpacking the Evidence for Their Use Today and Tomorrow
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
From Patient Evaluations to New Targeted Therapies
A Look at the Changing HIV Playing Field
Optimizing HIV Prevention in Primary Care
Multidimensional Outcomes With SGLT2 Inhibitors
Best Practices for Screening, Diagnosis, and Management
From the Airway Epithelium to Improved Patient Outcomes
Accelerating Diagnosis and Treatment
